Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Shelley Wood

December 02, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

L.A. McKeown

December 09, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

FREEDOM Substudy: CABG, PCI Outcomes Affected by Baseline BP

Yael L. Maxwell

August 30, 2015

News Daily News

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Todd Neale

August 17, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

May 07, 2015

News Conference News AHA 2014

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

November 16, 2014

News Daily News

Ischemia Testing Foretells Prognosis in Diabetic Patients with Asymptomatic CAD

Caitlin E. Cox

October 03, 2014

Presentation TCT 2012

Optimizing the Diabetic Formulary: Managing the Triad of Glycemic Control, Blood Pressure, and Hyperlipidemia

Presenter: Michael Farkouh

October 26, 2012

News Daily News

Pioglitazone Can Decrease Need for Revascularization in Diabetic Patients After BMS

L.A. McKeown

April 07, 2011

News Daily News

BARI 2D: Prompt Revascularization Improves Angina Symptoms in Diabetics

L.A. McKeown

April 01, 2011

Advertisement

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

FREEDOM Substudy: CABG, PCI Outcomes Affected by Baseline BP

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

Ischemia Testing Foretells Prognosis in Diabetic Patients with Asymptomatic CAD

Optimizing the Diabetic Formulary: Managing the Triad of Glycemic Control, Blood Pressure, and Hyperlipidemia

Pioglitazone Can Decrease Need for Revascularization in Diabetic Patients After BMS

BARI 2D: Prompt Revascularization Improves Angina Symptoms in Diabetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content